These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 4092105

  • 1. [Cancer of the prostate: subcapsular orchiectomy].
    Cukier J, Rivain T.
    Bull Cancer; 1985; 72(6):543-8. PubMed ID: 4092105
    [Abstract] [Full Text] [Related]

  • 2. [The potential hormonal therapy of prostatic carcinoma].
    Studer UE, Altwein J, Bartsch G.
    Urologe A; 1991 Sep; 30(5):310-6. PubMed ID: 1949440
    [Abstract] [Full Text] [Related]

  • 3. [Hormonal therapy (medical orchiectomy) in prostatic carcinoma].
    Studer UE, Münch D.
    Schweiz Med Wochenschr; 1990 Jun 16; 120(24):881-7. PubMed ID: 2193381
    [Abstract] [Full Text] [Related]

  • 4. Tamoxifen in refractory metastatic carcinoma of the prostate.
    Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H.
    Cancer Treat Rep; 1980 Jun 16; 64(6-7):813-8. PubMed ID: 7427966
    [Abstract] [Full Text] [Related]

  • 5. Long-term results of patients with clinical stage C prostate cancer treated by phototherapy and early orchiectomy. A retrospective analysis of 169 cases.
    Wiegel T, Tepel J, Schmidt R, Klosterhalfen H, Arps H, Berger P, Franke HD.
    Strahlenther Onkol; 1996 Nov 16; 172(11):596-603. PubMed ID: 8946031
    [Abstract] [Full Text] [Related]

  • 6. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 16; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M, Carlström K, Rozell BL, Stege R, Pousette A.
    Clin Cancer Res; 2000 May 16; 6(5):1790-5. PubMed ID: 10815899
    [Abstract] [Full Text] [Related]

  • 8. [Progress of endocrine therapy for prostate cancer and results].
    Kanetake H.
    Gan To Kagaku Ryoho; 1996 Mar 16; 23(4):413-7. PubMed ID: 8678491
    [Abstract] [Full Text] [Related]

  • 9. Hormonal therapy in prostatic carcinoma.
    Resnick MI.
    Urology; 1984 Nov 16; 24(5 Suppl):18-23. PubMed ID: 6388092
    [Abstract] [Full Text] [Related]

  • 10. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
    Boel K, Van Poppel H, Goethuys H, Derluyn J, Vandenbroucke F, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L.
    Anticancer Res; 1999 Nov 16; 19(3B):2157-61. PubMed ID: 10472324
    [Abstract] [Full Text] [Related]

  • 11. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M, García González JI, Mora Durvan M, Díez Rodríguez JM, Esteban Artiaga R, Navarro Sebastián J, Castro Pita M, Paniagua Andrés P.
    Actas Urol Esp; 1997 Sep 16; 21(8):724-36. PubMed ID: 9412221
    [Abstract] [Full Text] [Related]

  • 12. [Possibilities in drug therapy in prostatic carcinoma].
    Schmid HP.
    Ther Umsch; 1995 Jun 16; 52(6):418-22. PubMed ID: 7541571
    [Abstract] [Full Text] [Related]

  • 13. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 16; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 15. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
    Guinan P, Firfer R, Targonski P, Rubenstein M.
    Int Surg; 1993 Jul 01; 78(1):73-5. PubMed ID: 8473090
    [Abstract] [Full Text] [Related]

  • 16. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.
    Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN, Dietrich D.
    J Clin Oncol; 2004 Oct 15; 22(20):4109-18. PubMed ID: 15483020
    [Abstract] [Full Text] [Related]

  • 17. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
    Zhang XZ, Donovan MP, Williams BT, Mohler JL.
    Urology; 1996 Mar 15; 47(3):402-4. PubMed ID: 8633409
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 15; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 19. [Therapeutic options in advanced cancer of the prostate].
    Schmid HP, Bitton A.
    Praxis (Bern 1994); 1997 Oct 29; 86(44):1734-9. PubMed ID: 9446174
    [Abstract] [Full Text] [Related]

  • 20. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Oct 29; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.